15d-prostaglandin J2 inhibits inflammatory hypernociception: Involvement of peripheral opioid receptor

Journal of Pharmacology and Experimental Therapeutics

Volumn 324, Issue 1, 2008, Pages 313-321

  Napimoga, Marcelo H ^a,b   Souza, Guilherme R ^b   Cunha, Thiago M ^b   Ferrari, Luiz F ^b   Clemente Napimoga, Juliana T ^a   Parada, Carlos A ^b   Verri Jr , Waldiceu A ^b   Cunha, Fernando Q ^b   Ferreira, Sérgio H ^b  

^a UNIVERSITY OF UBERABA   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

1H 1,2,4 OXADIAZOLO[4,2 ALPHA]QUINOXALIN 1 ONE; 2 CHLORO 5 NITROBENZANILIDE; ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; CARRAGEENAN; CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE; CYCLIC GMP DEPENDENT PROTEIN KINASE INHIBITOR; FORMALDEHYDE; GLIBENCLAMIDE; GUANYLATE CYCLASE INHIBITOR; KT 5823; MORPHINE; N(G) METHYLARGININE; NALOXONE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; OPIATE; OPIATE RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; PROSTAGLANDIN E2; PROSTAGLANDIN J2; THIOGLYCOLIC ACID; UNCLASSIFIED DRUG; 15 DEOXYPROSTAGLANDIN J2; 15-DEOXYPROSTAGLANDIN J2; ANALGESIC AGENT; CYTOKINE; DRUG DERIVATIVE; PROSTAGLANDIN D2; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DRUG ADMINISTRATION ROUTE; DRUG MECHANISM; INFLAMMATION; INTRAGANGLIONAR DRUG ADMINISTRATION; MACROPHAGE; MALE; NOCICEPTION; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR UPREGULATION; SPINAL GANGLION; TEMPOROMANDIBULAR JOINT; ANIMAL; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; HYPERALGESIA; IMMUNOLOGY; PAIN; SKIN; WISTAR RAT;

ANALGESICS; ANIMALS; CARRAGEENAN; CYTOKINES; FORMALDEHYDE; HYPERALGESIA; INFLAMMATION; MACROPHAGES; MALE; NALOXONE; PAIN; PPAR GAMMA; PROSTAGLANDIN D2; RATS; RATS, WISTAR; RECEPTORS, OPIOID; SKIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 37349129573     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.126045     Document Type: Article

References (40)

1. Aley KO and Levine JD (1999) Role of protein kinase A in the maintenance of inflammatory pain. J Neurosci 19:2181-2186.
2. Alves D and Duarte I (2002) Involvement of ATP-sensitive K(+) channels in the peripheral antinociceptive effect induced by dipyrone. Eur J Pharmacol 444:47-52.
3. Belo AV, Barcelos LS, Ferreira MA, Teixeira MM, and Andrade SP (2004) Inhibition of inflammatory angiogenesis by distant subcutaneous tumor in mice. Life Sci 74:2827-2837.
4. Brack A, Labuz D, Schiltz A, Rittner HL, Machelska H, Schafer M, Reszka R, and Stein C (2004) Tissue monocytes/macrophages in inflammation: hyperalgesia versus opioid-mediated peripheral antinociception. Anesthesiology 101:204-211.
5. Burstein S (2005) PPAR-gamma: a nuclear receptor with affinity for cannabinoids. Life Sci 77:1674-1684.
6. Chatterjee PK, Patel NS, Cuzzocrea S, Brown PA, Stewart KN, Mota-Filipe H, Britti D, Eberhardt W, Pfeilschifter J, and Thiemermann C (2004) The cyclopentenone prostaglandin 15-deoxy-delta(12,14)-prostaglandin J2 ameliorates ischemic acute renal failure. Cardiovasc Res 61:630-643.
7. Clemente JT, Parada CA, Veiga MC, Gear RW, and Tambeli CH (2004) Sexual dimorphism in the antinociception mediated by kappa opioid receptors in the rat temporomandibular joint. Neurosci Lett 372:250-255.
8. Cunha FQ, Poole S, Lorenzetti BB, and Ferreira SH (1992) The pivotal role of tumor necrosis factor alpha in the development of inflammatory hyperalgesia. Br J Pharmacol 107:660-664.
9. Cunha TM, Verri WA Jr, Silva JS, Poole S, Cunha FQ, and Ferreira SH (2005) A cascade of cytokines mediates mechanical inflammatory hypernociception in mice. Proc Natl Acad Sci U S A 102:1755-1760.
10. Desreumaux P, Dubuquoy L, Nutten S, Peuchmaur M, Englaro W, Schoonjans K, Derijard B, Desvergne B, Wahli W, Chambon P, et al. (2001) Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic strategies. J Exp Med 193:827-838.
11. 2-induced inhibition of potassium currents in rat sensory neurones. J Physiol 516:163-178.
12. Ferrari LF, Cunha FQ, Parada CA, and Ferreira SH (2007) A novel technique to perform direct intraganglionar injections in rats. J Neurosci Methods 159:236-243.
13. Ferreira SH (1972) Prostaglandins, aspirin-like drugs and analgesia. Nat New Biol 240:200-203.
14. Ferreira SH (1979) A new method for measuring variations of rat paw volume. J Pharm Pharmacol 31:648.
15. Ferreira SH, Duarte ID, and Lorenzetti BB (1991) The molecular mechanism of action of peripheral morphine analgesia: stimulation of the cGMP system via nitric oxide release. Eur J Pharmacol 201:121-122.
16. 2-induced sensitization of rat sensory neurons in vitro. J Neurosci 18:10345-10355.
17. Ibrahim MM, Porreca F, Lai J, Albrecht PJ, Rice FL, Khodorova A, Davar G, Makriyannis A, Vanderah TW, Mata HP, et al. (2005) CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc Natl Acad Sci U S A 102:3093-3098.
18. Imbe H, Iwata K, Zhou Q, Zou S, Dubner R, and Ren K (2001) Orofacial deep and cutaneous tissue inflammation and trigeminal neuronal activation implications for persistent temporomandibular pain. Cells Tissues Organs 169:238-247.
19. Jiang C, Ting AT, and Seed B (1998) PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391: 82-86.
20. Kawahito Y, Kondo M, Tsubouchi Y, Hashiramoto A, Bishop-Bailey D, Inoue K, Kohno M, Yamada R, Hla T, and Sano H (2000) 15-deoxy-delta(12,14)-PGJ(2) induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats. J Clin Invest 106:189-197.
21. Khasar SG, Lin YH, Martin A, Dadgar J, McMahon T, Wang D, Hundle B, Aley KO, Isenberg W, McCarter G, et al. (1999) A novel nociceptor signaling pathway revealed in protein kinase C epsilon mutant mice. Neuron 24:253-260.
22. Levine JD and Taiwo YO (1989) Involvement of the mu-opiate receptor in peripheral analgesia. Neuroscience 32:571-575.
23. Lorenzetti BB and Ferreira SH (1985) Mode of analgesic action of dipyrone: direct antagonism of inflammatory hyperalgesia. Eur J Pharmacol 114:375-381.
24. LoVerme J, Russo R, La Rana G, Fu J, Farthing J, Mattace-Raso G, Meli R, Hohmann A, Calignano A, and Piomelli D (2006) Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-alpha. J Pharmacol Exp Ther 319:1051-1061.
25. Mousa SA, Schafer M, Mitchell WM, Hassan AH, and Stein C (1996) Local upregulation of corticotropin-releasing hormone and interleukin-1 receptors in rats with painful hindlimb inflammation. Eur J Pharmacol 311:221-231.
26. Oliveira AC, Bertollo CM, Rocha LT, Nascimento EB Jr, Costa KA, and Coelho MM (2007) Antinociceptive and antiedematogenic activities of fenofibrate, an agonist of PPAR alpha, and pioglitazone, an agonist of PPAR gamma. Eur J Pharmacol 561:194-201.
27. Ribeiro RA, Vale ML, Ferreira SH, and Cunha FQ (2000) Analgesic effect of thalidomide on inflammatory pain. Eur J Pharmacol 391:97-103.
28. Ricote M, Li AC, Willson TM, Kelly CJ, and Glass CK (1998) The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391:79-82.
29. Rodrigues LLFR, Oliveira MCG, Pelegrini-da-Silva A, Parada CA, and Tambeli CH (2006) Peripheral sympathetic component of the temporomandibular joint inflammatory pain in rats. J Pain 7:929-936.
30. Russo R, LoVerme J, La Rana G, D'Agostino G, Sasso O, Calignano A, and Piomelli D (2007) Synergistic antinociception by the cannabinoid receptor agonist anandamide and the PPAR-alpha receptor agonist GW7647. Eur J Pharmacol 566:117-119.
31. + channel pathway. Proc Natl Acad Sci U S A 101:3680-3685.
32. Schoonjans K, Martin G, Staels B, and Auwerx J (1997) Peroxisome proliferator-activated receptors, orphans with ligands and functions. Curr Opin Lipidol 8:159-166.
33. Stein C, Schafer M, and Machelska H (2003) Attacking pain at its source: new perspectives on opioids. Nat Med 9:1003-1008.
34. Straus DS, Pascual G, Li M, Welch JS, Ricote M, Hsiang CH, Sengchanthalangsy LL, Ghosh G, and Glass CK (2000) 15-deoxy-delta 12,14-prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway. Proc Natl Acad Sci U S A 97:4844-4849.
35. Su CG, Wen X, Bailey ST, Jiang W, Rangwala SM, Keilbaugh SA, Flanigan A, Murthy S, Lazar MA, and Wu GD (1999) A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. J Clin Invest 104:383-389.
36. Verri WA Jr, Cunha TM, Parada CA, Poole S, Cunha FQ, and Ferreira SH (2006) Hypernociceptive role of cytokines and chemokines: targets for analgesic drug development? Pharmacol Ther 112:116-138.
37. Vivancos GG, Parada CA, and Ferreira SH (2003) Opposite nociceptive effects of the arginine/NO/cGMP pathway stimulation in dermal and subcutaneous tissues. Br J Pharmacol 138:1351-1357.
38. Vivancos GG, Verri WA Jr, Cunha TM, Schivo IR, Parada CA, Cunha FQ, and Ferreira SH (2004) An electronic pressure-meter nociception paw test for rats. Braz J Med Biol Res 37:391-399.
39. Willoughby DA, Moore AR, and Colville-Nash PR (2000) Cyclopentenone prostaglandins-new allies in the war on inflammation. Nat Med 6:137-138.
40. Zingarelli B, Sheehan M, Hake PW, O'Connor M, Denenberg A, and Cook JA (2003) Peroxisome proliferator activator receptor-gamma ligands, 15-deoxy-delta(12,14)-prostaglandin J2 and ciglitazone, reduce systemic inflammation in polymicrobial sepsis by modulation of signal transduction pathways. J Immunol 171:6827-6837.